





HOW IS JAPANESE ENCEPHALITIS TRANSMITTED?

- The virus causing JE is a flavivirus related to dengue, yellow fever, and West Nile viruses ^(1, 4).
- It is transmitted by mosquitoes belonging to the *Culex* family.
- These mosquitoes breed in water and flooded rice fields and bite mainly in the evening and during the night ⁽¹⁻²⁾.
- The transmission cycle of the virus includes mosquitoes, pigs, and wading birds such as herons and egrets ⁽³⁻⁴⁾.
- The virus reproduces in pigs and birds (“amplifying hosts”) and infects mosquitoes that take blood meals from them ⁽¹⁻³⁻⁴⁾.
- Infected humans do not pass on the virus to feeding mosquitoes and are therefore considered dead-end hosts ⁽¹⁻²⁾.
- The virus tends to spill over into human populations when infected mosquito populations build up explosively and the human biting rate increases ⁽³⁾.



FROM JAPAN TO SOUTH-EAST ASIA & THE WESTERN PACIFIC REGION

- The first case of JE was documented in 1871 in Japan ⁽⁴⁾.
- It has since spread to almost all Asian countries, whether temperate, tropical or subtropical ⁽¹⁾.
- Some 24 countries are at risk mainly in South-East Asia and in the Western Pacific Region, as defined by the World Health Organization (WHO) ⁽¹⁾.
- The spread of JE virus in new areas has been associated with agricultural development and intensive rice production supported by irrigation programs ⁽⁴⁾.
- The JE virus cannot be eliminated due to the animal reservoirs, but human vaccination in endemic areas could control the disease ⁽¹⁾.
- While essentially a rural disease, JE cases have been reported in cities ⁽¹⁾.
- Risk factors include living nearby rice fields and in close proximity with pigs and/or water birds ⁽¹⁻⁴⁾.



NO SPECIFIC CURE, BUT PREVENTABLE THROUGH VACCINATION

- There is no specific cure for Japanese Encephalitis. Treatment consists in relieving symptoms and helping patients overcome the disease ⁽¹⁻⁴⁾.
- Vaccination is the most important preventive measure, and WHO recommends that JE vaccination be integrated into national immunization programs where JE is a public health priority ⁽¹⁾.
- The Sanofi Pasteur vaccine against JE
 - was first registered in Australia in 2010 and received WHO prequalification status in 2014
 - is a recombinant live-attenuated vaccine
 - requires a single dose in adults
 - in children, a booster dose is recommended 12-24 months after the primary injection to ensure long-term protection.

NEARLY **70,000** ⁽¹⁾ JAPANESE ENCEPHALITIS CASES PER YEAR



UP TO **20,400** DEATHS




30% OF SEVERE CASES DEVELOP SERIOUS SEQUELAE

TRAVELERS ARE AT RISK OF JAPANESE ENCEPHALITIS

- JE can also affect children and adults travelling in countries where the JE virus is endemic.
- Personal preventive measures include
 - the use of mosquito repellents,
 - long-sleeved clothes,
 - coils and vaporizers ⁽⁴⁾.
- Travelers spending extensive time in JE endemic areas are recommended to get vaccinated before travel ⁽²⁾.
- The U.S. Advisory Committee on Immunization practices (ACIP) specifically recommends JE vaccination ⁽²⁾
 - for travelers who plan to spend a month or longer in endemic areas
 - for frequent travelers to JE-endemic areas
 - for short-term (<1 month) travelers to endemic areas if they plan to travel outside of an urban area
 - for those who are uncertain about their travel duration, destinations or activities.
- JE vaccination is not recommended for travelers with very-low risk itineraries, such as shorter-term travel limited to urban areas or outside of a well-defined JE virus transmission season ⁽²⁾.

JAPANESE ENCEPHALITIS SYMPTOMS ⁽¹⁾

- The first signs appear after an incubation period of 4 to 14 days.
- Abrupt onset of high fever is associated with myalgia, headache, painful neck stiffness and vomiting
- Children may present with nausea, vomiting and abdominal pain as initial symptoms.
- Patient's condition can deteriorate rapidly, ultimately leading to coma.
- Convulsions experienced by 75% of patients
- About 30% of survivors develop serious neurological sequelae



REFERENCES

¹ WHO, WEEKLY EPIDEMIOLOGICAL RECORD, NO. 9, 27 FEBRUARY 2015

² CDC. Japanese Encephalitis Vaccines - Recommendations of the Advisory Committee on Immunization Practices (ACIP) Info: Morbidity and Mortality Weekly Report. July 19, 2019, 68(2)1-33. Available at <https://www.cdc.gov/mmwr/volumes/68/rr/rr6802a1.htm>

³ WHO Water-related diseases available at https://www.who.int/water_sanitation_health/diseases-risks/diseases/encephalitis/en/

⁴ WHO factsheet Japanese encephalitis. 9 May 2019. Available at: <https://www.who.int/en/news-room/fact-sheets/detail/japanese-encephalitis>



SANOFI PASTEUR

www.sanofipasteur.com
14 Espace Henry Vallée
69007 Lyon - France

Follow us on



YouTube